Department of Gynecology, Cancer Hospital of China Medical University, Liaoning Cancer Institute and Hospital, No. 44, Xiaoheyan Road, Shenyang 110042, Liaoning Province, China.
Central Laboratory, Cancer Hospital of China Medical University, Liaoning Cancer Institute and Hospital, No. 44, Xiaoheyan Road, Shenyang 110042, Liaoning Province, China.
Int Immunopharmacol. 2021 Jul;96:107714. doi: 10.1016/j.intimp.2021.107714. Epub 2021 May 11.
Naltrexone (NTX) is a nonspecific opioid antagonist that exerts pharmacological effects on the opioid axis by blocking opioid receptors distributed in cytoplastic and nuclear regions. NTX has been used in opioid use disorder (OUD), immune-associated diseases, alcoholism, obesity, and chronic pain for decades. However, low-dose naltrexone (LDN) also exhibits remarkable inhibition of DNA synthesis, viability, and other functions in numerous cancers and is involved in immune remodeling against tumor invasion and chemical toxicity. The potential anticancer activity of LDN is a focus of basic research. Herein, we summarize the associated studies on LDN oncotherapy to highlight the potential mechanisms and prospective clinical applications.
纳曲酮（NTX）是一种非特异性阿片受体拮抗剂，通过阻断分布在细胞质和核区域的阿片受体，发挥对阿片轴的药理学作用。几十年来，NTX 已被用于治疗阿片类药物使用障碍（OUD）、免疫相关疾病、酒精中毒、肥胖和慢性疼痛。然而，低剂量纳曲酮（LDN）也对许多癌症中的 DNA 合成、活力和其他功能表现出显著的抑制作用，并参与针对肿瘤侵袭和化学毒性的免疫重塑。LDN 的潜在抗癌活性是基础研究的重点。本文总结了 LDN 肿瘤治疗相关的研究，以突出潜在的机制和前瞻性临床应用。
